{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:08:26Z","timestamp":1780456106949,"version":"3.54.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study aims to determine frequency and reasons for prematurely discontinuing or switching antiplatelet therapy in elderly patients admitted with non-ST-elevation acute coronary syndrome (NSTE-ACS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>Patients of 75 years or older admitted with suspected NSTE-ACS were included between 2013 and 2016. Information was extracted from the patients\u2019 medical files.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 544 patients were included, 17.3% discontinued aspirin within one year, predominantly (57%) within 30 days. The most common reason was the start of a (non-vitamin-K) oral anticoagulant [(N)OAC], either combined with a P2Y<jats:sub>12<\/jats:sub>-inhibitor (43%) or as monotherapy (16%). The P2Y<jats:sub>12<\/jats:sub>-inhibitor was discontinued in 31.2% of patients within one year, of which 46% within 30 days. The most common reason was undergoing coronary artery bypass grafting (CABG; 22%). Switching of clopidogrel seldom occurred; however, ticagrelor was switched in 50\/179 patients mainly due to dyspnoea (42%). Independent predictors for prematurely discontinuing antiplatelet therapy were undergoing CABG [odds ratio (OR) 3.257 (95% confidence interval [CI] 1.836\u20135.779)], need for (N)OAC [OR 2.167 (95% CI 1.423\u20133.300)] and type II ACS as final diagnosis [OR 3.793 (95% CI 1.721\u20138.361)]. Undergoing percutaneous coronary intervention [OR 0.393 (95% CI 0.243\u20130.634)] and use of clopidogrel [OR 0.441(95% CI 0.293\u20130.662)] were independent predictors of continuing antiplatelet therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In elderly patients of at least 75 years with NSTE-ACS, antiplatelet therapy is frequently discontinued prematurely, most often within 30 days. Main reasons for discontinuing are need for (N)OAC, undergoing CABG or type II ACS as final diagnosis and suffering from dyspnoea while on ticagrelor.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000000787","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T15:43:10Z","timestamp":1571067790000},"page":"66-72","source":"Crossref","is-referenced-by-count":12,"title":["Reasons for early discontinuing or switching of antiplatelet therapy in elderly patients after acute coronary syndrome"],"prefix":"10.1097","volume":"31","author":[{"given":"Marieke E.","family":"Gimbel","sequence":"first","affiliation":[{"name":"Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit J. A.","family":"Vos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuc A.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes C.","family":"Kelder","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurri\u00ebn M.","family":"ten Berg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230924","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes.","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"R2-20230924","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R3-20230924","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"R4-20230924","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"R5-20230924","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3109\/09537104.2015.1119815","article-title":"Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry.","volume":"27","author":"Biscaglia","year":"2016","journal-title":"Platelets"},{"key":"R6-20230924","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/ehjcvp\/pvy018","article-title":"Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry.","volume":"4","author":"Zeymer","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R7-20230924","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jcin.2014.10.017","article-title":"Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.","volume":"8","author":"Cutlip","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"R8-20230924","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"key":"R9-20230924","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MCA.0000000000000623","article-title":"Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial.","volume":"29","author":"Yan","year":"2018","journal-title":"Coron Artery Dis"},{"key":"R10-20230924","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/imj.13595","article-title":"Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?.","volume":"47","author":"Harding","year":"2017","journal-title":"Intern Med J"},{"key":"R11-20230924","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000475705","article-title":"Incidence and causes for early ticagrelor discontinuation: a \u2018real-world\u2019 dutch registry experience.","volume":"138","author":"Bergmeijer","year":"2017","journal-title":"Cardiology"},{"key":"R12-20230924","doi-asserted-by":"crossref","first-page":"e006132","DOI":"10.1161\/CIRCINTERVENTIONS.117.006132","article-title":"Frequency, reasons, and impact of premature ticagrelor discontinuation in patients undergoing coronary revascularization in routine clinical practice: results from the Bern percutaneous coronary intervention registry.","volume":"11","author":"Zanchin","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"R13-20230924","doi-asserted-by":"crossref","first-page":"e008085","DOI":"10.1161\/JAHA.117.008085","article-title":"Predictors, and clinical impact of early prasugrel cessation in patients with ST-elevation myocardial infarction.","volume":"7","author":"Koskinas","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"R14-20230924","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:07:20Z","timestamp":1695539240000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000787","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}